Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant added to cisplatin-etoposide in metastatic lung carcinoma
NL-OMON31383Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aprepitant, etoposide and cisplatin in chemotherapy-induced nausea and vomiting (CINV) and bronchial carcinoma (2 arms), sponsored by Radboud University Medical Center. Planned start Jan 2008; status: not yet recruiting.
02
Drugs
aprepitantetoposidecisplatin
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON31383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31383.